Loading
A phase 1/2 trial of Pembrolizumab, Ipilimumab in melanoma and uveal melanoma, run by BioInvent International AB, active and no longer recruiting.
Different Doses of BI-1607 in Combination With Pembrolizumab and Ipilimumab, in Participants With Unresectable or Metastatic Melanoma is a phase 1/2 interventional study registered as NCT06784648 by BioInvent International AB, with 35 participants planned, started 2024-12-11 and due to reach its primary completion in 2025-12-30. Interventions recorded: pembrolizumab (KEYTRUDA®), BI-1607, Ipilimumab (YervoyTM, 50 mg/10 mL solution). Conditions listed: Melanoma Metastatic, Melanoma of Skin, Melanoma BRAF V600E/K Mutated, Melanoma Recurrent. No results are recorded here; the registry entry is the source.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares BioInvent International, Melanoma, Pembrolizumab, Immune checkpoint inhibitors.
Shares Uveal melanoma, Advanced melanoma (unresectable stage III and stage IV), Melanoma, Pembrolizumab.
Shares BioInvent International, Pembrolizumab, Immune checkpoint inhibitors.
Shares Uveal melanoma, Ipilimumab, Melanoma, Immune checkpoint inhibitors.
Shares Advanced melanoma (unresectable stage III and stage IV), Melanoma, Pembrolizumab, Immune checkpoint inhibitors.
Shares Advanced melanoma (unresectable stage III and stage IV), Melanoma, Pembrolizumab, Immune checkpoint inhibitors.
Shares Advanced melanoma (unresectable stage III and stage IV), Melanoma, Pembrolizumab, Immune checkpoint inhibitors.
Shares Uveal melanoma, Advanced melanoma (unresectable stage III and stage IV), Melanoma.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/